PDL1抑制剂[+1] 在研机构 上海复星医药产业发展有限公司[+1] 原研机构 上海复宏汉霖生物制药有限公司 在研适应症 实体瘤[+3] 非在研适应症 广泛期小细胞肺癌[+1] 最高研发阶段临床2期 首次获批国家/地区- 首次获批日期1800-01-20 PM-1022 靶点 PDL1 x TIGIT 作用机制 PDL1抑制剂[+1] 在研机构 原研...
RESULTS: Tumoral PDL1 expression (25%), which was seen in 21% of patients (14 of 66), significantly correlated with mixed histology, tumor thickness, mitoses, recurrence, and metastasis. According to linear regression analysis, tumoral PDL1 expression correlated with thickness (P=.0041); p53 ...
Prior to the advent of PD1/PDL1 checkpoint inhibitors, systemic chemotherapy with cisplatin-based regimens was the standard of care, leading to median survival of around 1 year.Citation5,Citation6For patients with platinum-refractory disease, the median survival was only 6–9 months.Citation7–Cita...
Histology revealed severe inflammation in the heart and skeletal muscles. These results suggest that deficiency of PDL1 in NOD background has the potential to lead to immune-mediated tissue damage in organs other than the pancreas, but this cannot be appreciated in PDL1−/−.NOD mice as ...
Among patients with squamous histology, the median OS was 8.9 months in the atezolizumab cohort (n = 112) versus 7.7 months on the docetaxel arm (n = 110; HR, 0.73; 95% CI, 0.54-0.98). Regarding PD-L1 status, PD-L1—positive patients (TC1/2/3 or IC1/2/3) had expression on ...
In the open-label, randomized, phase III KEYNOTE-181 trial (NCT02564263), pembrolizumab was associated with a statistically significant improvement in OS compared with either paclitaxel, docetaxel, or irinotecan in patients with a PD-L1 combined positive score (CPS) ≥10, regardless of histology....
P2.01-048 Paired Comparison of PDL1 Assessment on Cytology and Histology from Malignancies in the Lung: Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapydoi:10.1016/j.jtho.2016.11.1100Birgit,SkovTorsten,SkovJournal of Thoracic Oncology...
Immunohistology on the tumor tissues post-necropsy indicated that the treatment inhibited PD-L1 and induced a cytotoxic immune response. Finally, as an initial measurement of tissue damage due to the treatment, we analyzed major organs by histopathology and saw no differences from the vehicle-...
In NSCLC, ORs were observed irrespective of histology. Conclusions: BMS-936559 was active and generally well tolerated in pts with NSCLC, RCC, and MEL. In conjunction with data from anti-PD-1/BMS-936558 trials, this study concurrently validates the importance of the PD-...
Regarding histology, 92% had squamous cell carcinoma, 6% had adenocarcinoma, and 1% had adenosquamous carcinoma. Ninety-five percent of patients had M1 disease and 5% had recurrent disease. PD-L1 status was determined using the PD-L1 IHC 22C3 pharmDx Kit. Patients received 200 mg of pembroliz...